Qube Research & Technologies LTD Sesen Bio, Inc. Transaction History

Qube Research & Technologies LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.49 - $0.61 $64,067 - $79,758	-130,751 Reduced 90.53%	13,674 $8,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $0.93 $0 - $23,630	-25,409 Reduced 14.96%	144,425 $61,000
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.89 $64,536 - $151,152	169,834 New	169,834 $138,000
Q2 2021 Aug 13, 2021	SELL	$2.18 - $4.66 $340,138 - $727,085	-156,027 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$1.3 - $3.24 $226,558 - $564,654	-174,276 Reduced 52.76%	156,027 $406,000
Q4 2020 Feb 16, 2021	SELL	$1.01 - $1.77 $304,815 - $534,182	-301,798 Reduced 47.75%	330,303 $446,000
Q3 2020 Nov 12, 2020	BUY	$0.67 - $1.4 $367,257 - $767,404	548,146 Added 652.9%	632,101 $885,000
Q2 2020 Aug 14, 2020	BUY	$0.52 - $0.87 $43,656 - $73,040	83,955 New	83,955 $60,000
Q1 2020 May 15, 2020	SELL	$0.39 - $1.03 $97,984 - $258,780	-251,243 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$0.89 - $1.5 $223,606 - $376,864	251,243 New	251,243 $261,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.